BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38250731)

  • 21. [Value of (18)F-FDG PET-CT imaging to predict epidermal growth factor receptor mutations in patients with lung squamous cell carcinoma].
    Zhao CY; Deng XY; Wang HS; Cao GP; Ding JN; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2021 Jul; 43(7):795-800. PubMed ID: 34289575
    [No Abstract]   [Full Text] [Related]  

  • 22. Prognostic Value of Baseline and Interim Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT in Patients with Follicular Lymphoma.
    Liang JH; Zhang YP; Xia J; Ding CY; Wu W; Wang L; Cao L; Zhu HY; Fan L; Li TN; Li JY; Xu W
    Cancer Res Treat; 2019 Oct; 51(4):1479-1487. PubMed ID: 30913868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of the methodological aspects of the dichotomization of total metabolic tumor volume measured through baseline fluorine-18 fluorodeoxyglucose PET on survival prediction in lymphoma.
    Lue KH; Chen YH; Wu YF; Liu SH
    Nucl Med Commun; 2023 Jan; 44(1):74-80. PubMed ID: 36514929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Significance Of Sequential 18f-fdg Pet/Ct During Frontline Treatment Of Peripheral T Cell Lymphomas.
    Song GY; Jung SH; Ahn SY; Kim M; Ahn JS; Lee JJ; Kim HJ; Moon JB; Yoo SW; Kwon SY; Min JJ; Bom HS; Kang SR; Yang DH
    Korean J Intern Med; 2024 Mar; 39(2):327-337. PubMed ID: 38268194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma.
    Cottereau AS; Lanic H; Mareschal S; Meignan M; Vera P; Tilly H; Jardin F; Becker S
    Clin Cancer Res; 2016 Aug; 22(15):3801-9. PubMed ID: 26936916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incorporating radiomic feature of pretreatment 18F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinoma.
    Chen YH; Wang TF; Chu SC; Lin CB; Wang LY; Lue KH; Liu SH; Chan SC
    PLoS One; 2020; 15(12):e0244502. PubMed ID: 33370365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors.
    Seban RD; Mezquita L; Berenbaum A; Dercle L; Botticella A; Le Pechoux C; Caramella C; Deutsch E; Grimaldi S; Adam J; Ammari S; Planchard D; Leboulleux S; Besse B
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1147-1157. PubMed ID: 31754795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of the metabolic bulk volume in patients with diffuse large B-cell lymphoma on baseline
    Delaby G; Hubaut MA; Morschhauser F; Besson A; Huglo D; Herbaux C; Baillet C
    Leuk Lymphoma; 2020 Jul; 61(7):1584-1591. PubMed ID: 32100597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Total lesion glycolysis determined per RECIST 1.1 criteria predicts survival in EGFR mutation-negative patients with advanced lung adenocarcinoma.
    Ho TY; Chou PC; Yang CT; Tsang NM; Yen TC
    Clin Nucl Med; 2015 Jun; 40(6):e295-9. PubMed ID: 25783515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Role of 18F-FDG PET/CT on Staging and Prognosis in Patients with Small Cell Lung Cancer.
    Zer A; Domachevsky L; Rapson Y; Nidam M; Flex D; Allen AM; Stemmer SM; Groshar D; Bernstine H
    Eur Radiol; 2016 Sep; 26(9):3155-61. PubMed ID: 26685851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma.
    Cottereau AS; Hapdey S; Chartier L; Modzelewski R; Casasnovas O; Itti E; Tilly H; Vera P; Meignan MA; Becker S
    J Nucl Med; 2017 Feb; 58(2):276-281. PubMed ID: 27754905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The prognostic relationship of 18F-FDG PET/CT metabolic and volumetric parameters in metastatic ALK + NSCLC.
    Agüloğlu N; Aksu A; Unat DS; Akyol M
    Nucl Med Commun; 2022 Dec; 43(12):1217-1224. PubMed ID: 36345766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial.
    Girum KB; Cottereau AS; Vercellino L; Rebaud L; Clerc J; Casasnovas O; Morschhauser F; Thieblemont C; Buvat I
    J Nucl Med; 2024 Feb; 65(2):313-319. PubMed ID: 38071535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Volumetric parameters from [
    Langen Stokmo H; Aly M; Bowitz Lothe IM; Borja AJ; Mehdizadeh Seraj S; Ghorpade R; Miao X; Hjortland GO; Malinen E; Sorbye H; Werner TJ; Alavi A; Revheim ME
    J Neuroendocrinol; 2022 Jul; 34(7):e13170. PubMed ID: 35729738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor metabolic and secondary lymphoid organ metabolic markers on 18F-fludeoxyglucose positron emission tomography predict prognosis of immune checkpoint inhibitors in advanced lung cancer.
    Jin P; Bai M; Liu J; Yu J; Meng X
    Front Immunol; 2022; 13():1004351. PubMed ID: 36341372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis.
    Guo B; Tan X; Ke Q; Cen H
    PLoS One; 2019; 14(1):e0210224. PubMed ID: 30625203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.
    Mak RH; Digumarthy SR; Muzikansky A; Engelman JA; Shepard JA; Choi NC; Sequist LV
    Oncologist; 2011; 16(3):319-26. PubMed ID: 21339258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies.
    Meignan M; Cottereau AS; Versari A; Chartier L; Dupuis J; Boussetta S; Grassi I; Casasnovas RO; Haioun C; Tilly H; Tarantino V; Dubreuil J; Federico M; Salles G; Luminari S; Trotman J
    J Clin Oncol; 2016 Oct; 34(30):3618-3626. PubMed ID: 27551111
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive value of multiple metabolic and heterogeneity parameters of
    Shi A; Wang J; Wang Y; Guo G; Fan C; Liu J
    Ann Nucl Med; 2022 Apr; 36(4):393-400. PubMed ID: 35084711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of baseline
    Zhou Y; Hong Z; Zhou M; Sang S; Zhang B; Li J; Li Q; Wu Y; Deng S
    J Med Imaging Radiat Oncol; 2020 Feb; 64(1):87-95. PubMed ID: 31880103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.